Overview

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (>50%) risk of future life-threatening recurrences and death.

Eligibility

Inclusion Criteria:

• Age ≥18 years.
• Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
• Surgically resectable disease following neoadjuvant systemic treatment.
• At least one of the following must be true:
  1. Received at least 4 weeks of neoadjuvant endocrine therapy with minimal or no decrease in tumor size by MRI, US or physical examination at discontinuation/completion of neoadjuvant endocrine therapy
  2. Received at least 2 months of neoadjuvant chemotherapy with evidence of at least 1 cm of residual disease by MRI, US or physical examination at discontinuation/completion of neoadjuvant endocrine therapy
  3. Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, US or physical examination
• Provide written informed consent.
• Willing to return to enrolling institution for breast cancer surgery.
• Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
• Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
• Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic.

Exclusion Criteria:

• Ineligible for surgery.
• History of prior malignancy <5 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, carcinoma in situ of the cervix.